{
    "mainTopic": {
        "title": "Aortic stenosis",
        "content_info": "The materials for the topics can be found in the uploaded pdf files. The informations about the different topics listed on the ppt pages are sometimes limited and do not contain the necessary amount of content because of it's dense format, therefore it does not include every information but serves as a great foundation to form the questions and provide focus on core content, however additional background knowledge is needed to create quality revision quizzes.",
        "subTopics": [
            {
                "title": "Etiology, Pathophysiology",
                "quizzes": [
                    {
                        "question": "Which of the following statements accurately delineates the interplay of genetic predisposition and environmental factors in the pathogenesis of the disease, emphasizing the molecular mechanisms that underpin this interaction?",
                        "goodAnswer": "The disease etiology is characterized by a multifactorial origin, wherein genetic variants, particularly in genes encoding for immune regulatory proteins like those within the HLA complex and non-HLA genes such as PTPN22 and IRF5, interact with environmental triggers, including viral infections (e.g., EBV) and UV radiation, to disrupt immune tolerance, leading to chronic autoimmune inflammation.",
                        "wrongAnswer_1": "The disease is primarily triggered by singular, high-penetrance genetic mutations that directly cause cellular dysfunction within target organs, with environmental factors playing a negligible role, mainly influencing the disease progression rate rather than its initiation or fundamental autoimmune mechanisms.",
                        "wrongAnswer_2": "Environmental exposures, specifically to industrial pollutants and heavy metals, are the sole etiological agents, directly inducing epigenetic modifications that lead to widespread systemic inflammation and tissue damage, independent of any pre-existing genetic susceptibilities or immune system dysregulation.",
                        "wrongAnswer_3": "The primary etiological factor is attributed to chronic bacterial infections that initiate a polyclonal B-cell activation, resulting in the production of non-specific autoantibodies and subsequent immune complex deposition, with genetic factors contributing only to the severity of infectious episodes but not to the autoimmune pathway.",
                        "wrongAnswer_4": "Psychological stress is the dominant etiological factor, leading to neuroendocrine imbalances that directly suppress regulatory T-cell function and promote a generalized pro-inflammatory state, thereby triggering autoimmunity in the absence of specific genetic predispositions or defined environmental triggers."
                    },
                    {
                        "question": "In dissecting the pathophysiological cascade, identify the most proximal event at the cellular level and its immediate molecular consequence that initiates the chronic inflammatory process and subsequent tissue injury characteristic of the disease.",
                        "goodAnswer": "The initiating event in pathogenesis is often the failure of central and peripheral tolerance mechanisms, leading to the activation of autoreactive T cells, specifically CD4+ T helper cells, which then secrete pro-inflammatory cytokines such as TNF-\u03b1, IL-6, and IL-17, thereby activating macrophages and B cells, and promoting a sustained inflammatory response and tissue damage through cytotoxic T lymphocytes and autoantibody production.",
                        "wrongAnswer_1": "The primary initiating event is the uncontrolled activation of the complement system, particularly the classical pathway, due to spontaneous C1q binding to apoptotic blebs, leading to chronic inflammation and tissue damage via direct lysis and anaphylatoxin production, independent of initial T cell activation or cytokine release.",
                        "wrongAnswer_2": "Pathogenesis begins with the dysregulation of natural killer (NK) cells, causing them to lose tolerance to self-antigens and directly lyse healthy cells via perforin and granzyme release, initiating tissue injury and inflammation, with subsequent adaptive immune responses playing a secondary role in perpetuating damage.",
                        "wrongAnswer_3": "The disease process is initiated by the aberrant activation of mast cells in tissues, leading to chronic release of histamine, leukotrienes, and prostaglandins, causing vasodilation, edema, and inflammation, with subsequent recruitment of neutrophils and eosinophils contributing to tissue damage, independent of T cell or B cell involvement.",
                        "wrongAnswer_4": "The initial pathogenic event is the widespread deposition of circulating immune complexes composed of self-antigens and non-specific immunoglobulins, activating the alternative complement pathway and triggering chronic inflammation and tissue injury, without requiring initial T cell activation or a defined autoreactive T cell population."
                    },
                    {
                        "question": "Elucidate the specific role of HLA class II alleles, particularly HLA-DRB1, in mediating genetic susceptibility to the disease, detailing the molecular mechanisms through which these alleles influence antigen presentation and subsequent autoimmune responses.",
                        "goodAnswer": "Specific HLA-DRB1 alleles, such as HLA-DRB1*15:01 and HLA-DRB1*03:01, are strongly associated with increased disease susceptibility due to their structural motifs within the peptide-binding groove, which preferentially bind and present self-antigens derived from intracellular proteins to CD4+ T cells with high affinity, thereby breaking T cell tolerance and initiating autoimmune responses. This enhanced presentation of self-antigens promotes T cell activation and cytokine production, driving chronic inflammation.",
                        "wrongAnswer_1": "HLA class I alleles, specifically HLA-B27, are the primary genetic determinants of susceptibility, as they are crucial for presenting intracellular antigens to CD8+ cytotoxic T cells, leading to direct cell lysis and tissue damage. HLA-DRB1 alleles play a negligible role, mainly influencing the severity of joint involvement but not the overall autoimmune process.",
                        "wrongAnswer_2": "Genetic susceptibility is primarily conferred by HLA class III alleles, which encode for complement components C4A and C4B. Deficiencies in these components lead to impaired clearance of immune complexes and apoptotic debris, increasing the risk of autoimmunity. HLA-DRB1 alleles have no direct role in antigen presentation or T cell activation.",
                        "wrongAnswer_3": "The primary role of HLA-DRB1 alleles is to influence B cell activation and autoantibody production. Certain HLA-DRB1 alleles enhance B cell receptor signaling and promote the survival of autoreactive B cell clones, leading to increased production of pathogenic autoantibodies and subsequent immune complex disease. T cell presentation is not directly affected by HLA-DRB1.",
                        "wrongAnswer_4": "HLA-DRB1 alleles primarily modulate the innate immune response by influencing the expression of Toll-like receptors (TLRs) on macrophages and dendritic cells. Specific alleles enhance TLR signaling in response to microbial ligands, leading to excessive pro-inflammatory cytokine production and a predisposition to autoimmunity. Antigen presentation to T cells is not the primary mechanism."
                    }
                ]
            },
            {
                "title": "Clinical features",
                "quizzes": [
                    {
                        "question": "Which cluster of initial clinical manifestations most accurately reflects the prodromal phase of the disease, aiding in early recognition and differentiation from other rheumatologic conditions with overlapping symptomatology?",
                        "goodAnswer": "The prodromal phase is often characterized by non-specific systemic symptoms such as persistent fatigue, low-grade fever, myalgias, and arthralgias that are migratory in nature, along with subtle cutaneous findings like transient photosensitivity or mild, non-specific rashes, which may precede the onset of more specific organ involvement by months or even years, necessitating careful clinical evaluation and exclusion of other conditions like fibromyalgia or early rheumatoid arthritis.",
                        "wrongAnswer_1": "The initial presentation is typically acute and dramatic, marked by sudden onset of severe polyarthritis affecting large joints symmetrically, high fever, and a fixed, intensely erythematous rash resembling cellulitis, requiring immediate differentiation from septic arthritis and acute bacterial infections rather than other rheumatologic conditions.",
                        "wrongAnswer_2": "Early manifestations predominantly involve neurological symptoms, including acute psychosis, seizures, and cranial nerve palsies, accompanied by hypertension and rapidly progressive glomerulonephritis, mimicking primary central nervous system vasculitis or hypertensive encephalopathy rather than typical rheumatologic presentations.",
                        "wrongAnswer_3": "The disease onset is usually heralded by prominent gastrointestinal symptoms such as severe abdominal pain, bloody diarrhea, and weight loss, often misdiagnosed as inflammatory bowel disease exacerbation or acute mesenteric ischemia, with systemic features being secondary and less pronounced in the initial phase.",
                        "wrongAnswer_4": "The presenting symptoms are primarily cardiovascular, featuring acute onset of chest pain, shortness of breath, and palpitations, indicative of myocarditis or pericarditis with potential for rapid hemodynamic compromise, requiring immediate cardiac evaluation and differentiation from acute coronary syndromes rather than other rheumatologic diseases."
                    },
                    {
                        "question": "When evaluating disease activity and potential for long-term sequelae, which of the following clinical findings would be considered a critical indicator of major organ involvement and increased risk of irreversible damage, necessitating aggressive therapeutic intervention?",
                        "goodAnswer": "The presence of proliferative lupus nephritis, specifically Class III or IV nephritis based on renal biopsy, is a critical indicator of major organ involvement. This histological finding signifies active glomerular inflammation, associated with a high risk of progression to end-stage renal disease, cardiovascular events, and overall poor prognosis, mandating intensive immunosuppressive therapy and close monitoring.",
                        "wrongAnswer_1": "Mild discoid lupus lesions limited to the skin, without evidence of systemic symptoms or abnormal serology, are considered a major criterion for severe disease, indicating a high likelihood of systemic progression and internal organ damage, particularly renal and neurological involvement, thus requiring aggressive systemic treatment.",
                        "wrongAnswer_2": "Isolated lymphopenia with absolute lymphocyte counts consistently below 500/\u03bcL, in the absence of opportunistic infections or other cytopenias, is a major indicator of severe disease activity and poor prognosis, reflecting profound immune dysregulation and a high risk of developing lymphomas or other malignancies.",
                        "wrongAnswer_3": "Recurrent oral ulcers and alopecia, while common manifestations, are considered major criteria signifying severe disease activity and predicting a high risk of developing irreversible organ damage, especially affecting pulmonary hypertension and liver failure, warranting immediate escalation of immunosuppression.",
                        "wrongAnswer_4": "Raynaud's phenomenon and mild serositis, characterized by pleuritic chest pain and transient pleural effusions, are classified as major indicators of severe systemic disease, suggesting a high probability of progression to advanced cardiac and pulmonary complications, requiring immediate and intensive therapeutic management."
                    },
                    {
                        "question": "Distinguish between the clinical spectrum of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) based on their characteristic dermatological manifestations and the extent of systemic organ involvement, highlighting the patterns that differentiate these entities.",
                        "goodAnswer": "Cutaneous lupus erythematosus (CLE) encompasses a range of skin-limited conditions, including discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and acute cutaneous lupus erythematosus (ACLE, including malar rash), typically without significant systemic organ involvement beyond musculoskeletal symptoms. Systemic lupus erythematosus (SLE), in contrast, is defined by multisystem disease, potentially affecting renal, neurological, hematological, serosal, and cardiovascular systems, in addition to cutaneous manifestations, with overlapping skin lesions but broader systemic involvement.",
                        "wrongAnswer_1": "Both cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) invariably present with severe, life-threatening systemic involvement, including acute lupus nephritis and central nervous system lupus, with the primary distinction being the type of cutaneous lesions: CLE is characterized by bullous and vesicular lesions, while SLE presents with nodular and ulcerative skin findings.",
                        "wrongAnswer_2": "Systemic lupus erythematosus (SLE) is exclusively a dermatologic disease, characterized by widespread cutaneous lesions covering the entire body surface, including mucosal surfaces, whereas cutaneous lupus erythematosus (CLE) is defined by predominant systemic involvement, especially affecting the respiratory and gastrointestinal systems, but typically sparing the skin except for minor, transient rashes.",
                        "wrongAnswer_3": "Cutaneous lupus erythematosus (CLE) is defined by an acute onset of fulminant multisystem disease, mimicking septic shock with fever, hypotension, and disseminated intravascular coagulation, while systemic lupus erythematosus (SLE) presents with chronic, localized skin lesions primarily affecting non-sun-exposed areas and accompanied by severe internal organ damage from the outset.",
                        "wrongAnswer_4": "The fundamental distinction between CLE and SLE lies in their autoantibody profiles; cutaneous lupus erythematosus (CLE) is characterized by high titers of anti-dsDNA antibodies and markedly reduced complement levels, indicating robust systemic immune activation, whereas systemic lupus erythematosus (SLE) is associated with anti-Ro/SSA antibodies and normal complement levels, suggesting localized immune dysregulation limited to the skin and subcutaneous tissues."
                    }
                ]
            },
            {
                "title": "Diagnostic testing, Differential diagnosis",
                "quizzes": [
                    {
                        "question": "Which serological assay is recognized as the most sensitive initial screening tool for the disease, and what are its principal limitations in terms of diagnostic specificity when differentiating it from other autoimmune and non-autoimmune conditions?",
                        "goodAnswer": "The antinuclear antibody (ANA) test, performed by indirect immunofluorescence, exhibits high sensitivity for initial screening, demonstrating positivity in >95% of patients with the disease. However, its specificity is limited as ANA positivity can be observed in various other autoimmune disorders such as rheumatoid arthritis and Sjogren's syndrome, infections like viral hepatitis, and even in a small percentage of healthy individuals, necessitating further testing for disease-specific autoantibodies to enhance diagnostic accuracy.",
                        "wrongAnswer_1": "The anti-double-stranded DNA (anti-dsDNA) antibody assay is the most sensitive screening test, approaching 100% positivity in all affected individuals, and demonstrates high specificity for distinguishing the disease from other autoimmune conditions due to its direct pathogenic relevance and rare occurrence in other disorders.",
                        "wrongAnswer_2": "Measurement of serum complement levels (C3 and C4) serves as the most sensitive screening marker, consistently showing significant depression in early stages of the disease and high specificity for differentiating it from conditions with normal complement levels, thereby acting as a definitive initial diagnostic indicator.",
                        "wrongAnswer_3": "The erythrocyte sedimentation rate (ESR) is the most sensitive initial screening test, invariably elevated in active disease states and highly specific due to its direct correlation with the inflammatory burden, effectively distinguishing it from non-inflammatory conditions and serving as a primary diagnostic tool.",
                        "wrongAnswer_4": "The anti-Smith (anti-Sm) antibody assay is the most sensitive screening test, yielding positive results in nearly all cases and exhibiting exceptional specificity, making it the gold standard for initial diagnosis and differentiation from other autoimmune and non-autoimmune disorders, surpassing ANA in both sensitivity and specificity."
                    },
                    {
                        "question": "To enhance diagnostic precision and specificity following a positive initial screening test, which comprehensive panel of autoantibody assays is most judiciously recommended, and what is the specific clinical relevance of each antibody component within this panel for risk stratification and differential diagnosis?",
                        "goodAnswer": "Following a positive ANA screen, a confirmatory autoantibody panel should include assays for anti-dsDNA and anti-Sm antibodies, which exhibit high specificity for the disease, alongside anti-Ro/SSA and anti-La/SSB antibodies, indicative of Sjogren's syndrome and associated with photosensitivity and neonatal lupus, and antiphospholipid antibodies (aPL), which denote a risk for thrombotic events and pregnancy complications. This panel aids in refining diagnosis, assessing disease subsets, and predicting potential complications, thus guiding management strategies and risk stratification.",
                        "wrongAnswer_1": "A confirmatory panel should primarily focus on rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, which are essential for confirming the diagnosis and specifically differentiating it from rheumatoid arthritis, given the shared clinical features of joint involvement and systemic inflammation between these two autoimmune rheumatic diseases.",
                        "wrongAnswer_2": "Confirmatory testing should incorporate anti-mitochondrial antibodies (AMA) and anti-smooth muscle antibodies (ASMA), as these are highly specific for excluding primary biliary cholangitis and autoimmune hepatitis, respectively, which are common differential diagnoses presenting with fatigue, systemic symptoms, and potential liver enzyme abnormalities.",
                        "wrongAnswer_3": "The confirmatory panel should consist of anti-neutrophil cytoplasmic antibodies (ANCA), specifically c-ANCA and p-ANCA, to effectively differentiate it from ANCA-associated vasculitides, such as granulomatosis with polyangiitis and microscopic polyangiitis, which often manifest with renal and pulmonary involvement, creating significant clinical overlap.",
                        "wrongAnswer_4": "For diagnostic confirmation, it is crucial to test for anti-thyroglobulin and anti-thyroid peroxidase (anti-TPO) antibodies, as thyroid dysfunction is a frequent comorbidity in autoimmune diseases and can exacerbate systemic symptoms, potentially mimicking disease flares and complicating the clinical interpretation and management of the primary condition."
                    },
                    {
                        "question": "In formulating a differential diagnosis, which specific autoimmune and inflammatory conditions must be primarily considered due to substantial overlap in clinical and serological manifestations, and what are the key discriminatory features that aid in distinguishing each of these conditions from the disease in question?",
                        "goodAnswer": "Key differential diagnoses include rheumatoid arthritis (RA), differentiated by symmetrical small joint involvement, RF/anti-CCP positivity, and erosive joint changes versus variable joint involvement and anti-dsDNA/anti-Sm in the disease; Sjogren's syndrome, distinguished by prominent sicca symptoms, anti-Ro/SSA antibodies, and salivary/lacrimal gland dysfunction; and mixed connective tissue disease (MCTD), characterized by anti-U1RNP antibodies and overlapping features of the disease, scleroderma, and polymyositis, lacking renal specificity of the disease.",
                        "wrongAnswer_1": "Primary differential diagnoses are osteoarthritis (OA), distinguished by radiographic evidence of joint space narrowing and osteophytes in OA versus synovitis and erosions seen in the disease, and gout, characterized by acute monoarticular arthritis and uric acid crystal identification in synovial fluid in gout versus polyarticular and systemic features of the disease, easily differentiated by joint fluid analysis and radiographic findings.",
                        "wrongAnswer_2": "Differential diagnosis should primarily consider infectious diseases like Lyme disease and infectious mononucleosis, differentiated by specific serological tests for Borrelia burgdorferi and Epstein-Barr virus, respectively, and the transient nature of infections versus the chronic, relapsing course and persistent autoantibody presence in the disease, easily distinguishable by infection markers.",
                        "wrongAnswer_3": "Key differential diagnoses are fibromyalgia, differentiated by widespread pain and tenderness without objective synovitis or serological abnormalities in fibromyalgia versus objective synovitis, rash, and autoantibodies in the disease, and major depressive disorder, distinguished by predominant mood and neurovegetative symptoms without systemic inflammation or organ involvement characteristic of the disease, clinically distinct by physical exam and lab findings.",
                        "wrongAnswer_4": "Conditions to rule out include type 2 diabetes mellitus, differentiated by hyperglycemia, insulin resistance, and metabolic syndrome features in diabetes versus normal glucose metabolism and autoimmune markers in the disease, and asthma, distinguished by reversible airflow obstruction, bronchial hyperresponsiveness, and allergic triggers in asthma versus systemic inflammation, autoantibodies, and multi-organ involvement in the disease, easily differentiated by glucose levels and pulmonary function tests."
                    }
                ]
            },
            {
                "title": "Managemnet",
                "quizzes": [
                    {
                        "question": "What constitutes the foundational pharmacological strategy for managing mild to moderate disease activity, emphasizing its immunomodulatory mechanism and the primary clinical benefits observed in controlling disease manifestations?",
                        "goodAnswer": "Hydroxychloroquine (HCQ) serves as the cornerstone for managing mild to moderate disease activity, exerting its immunomodulatory effects by interfering with antigen processing within endosomes and lysosomes, and by reducing pro-inflammatory cytokine production. Clinically, HCQ effectively alleviates fatigue, arthralgia, and mucocutaneous symptoms, while also demonstrating long-term benefits in preventing disease flares, reducing the risk of thrombosis, and improving overall survival rates in patients with milder disease phenotypes.",
                        "wrongAnswer_1": "Prednisone is the primary agent for mild to moderate disease management, functioning as a potent anti-inflammatory by directly inhibiting phospholipase A2 and thereby prostaglandin and leukotriene synthesis, providing rapid symptomatic relief from acute flares characterized by fever and rash, but its use is restricted to short-term management due to significant long-term side effects and lack of substantial disease-modifying properties beyond symptom control.",
                        "wrongAnswer_2": "Methotrexate (MTX) is the foundational drug for mild to moderate disease, acting as a cytotoxic agent by inhibiting dihydrofolate reductase and subsequent purine and pyrimidine synthesis, effectively reducing lymphocyte proliferation and inflammatory responses, primarily targeting joint symptoms and preventing structural joint damage, though its use necessitates careful monitoring for myelosuppression and hepatic toxicity, limiting its broad applicability in milder cases.",
                        "wrongAnswer_3": "Cyclophosphamide (CYC) is the cornerstone for mild to moderate disease, functioning as a powerful alkylating agent that broadly suppresses the immune system by cross-linking DNA and inhibiting cell division, rapidly controlling systemic inflammation and severe organ involvement, making it suitable for initial remission induction even in milder cases, despite its significant risks of infection, malignancy, and infertility, typically reserved for more severe or refractory conditions.",
                        "wrongAnswer_4": "Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary pharmacological management for mild to moderate disease, acting as analgesic and anti-inflammatory agents by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), effectively relieving pain and fever associated with musculoskeletal symptoms, but providing only symptomatic relief without modifying the underlying disease course and carrying risks of gastrointestinal ulceration, cardiovascular events, and renal dysfunction with prolonged use."
                    },
                    {
                        "question": "For individuals exhibiting severe or refractory disease, particularly those with significant organ involvement, which immunosuppressive therapeutic strategies are typically indicated, and what are their respective mechanisms of action and specific clinical applications in managing these complex cases?",
                        "goodAnswer": "For severe or refractory disease, mycophenolate mofetil (MMF) and cyclophosphamide (CYC) are frequently employed. MMF inhibits inosine monophosphate dehydrogenase, thus suppressing purine synthesis and lymphocyte proliferation, particularly useful in lupus nephritis. CYC, an alkylating agent, broadly suppresses immune cell function, critical for organ-threatening flares. Biologic agents like belimumab (anti-BAFF antibody) and rituximab (anti-CD20 antibody) are also utilized for refractory cases, targeting B-cell survival and depletion respectively, offering targeted immunosuppression in complex clinical scenarios.",
                        "wrongAnswer_1": "Severe cases are primarily managed with high-dose methotrexate (MTX) and azathioprine (AZA). MTX, inhibiting dihydrofolate reductase, reduces cell proliferation mainly affecting T-cells, while AZA, a purine analog, interferes with DNA synthesis, both effective for long-term maintenance and controlling chronic inflammation, but less potent for acute severe flares or rapidly progressing organ involvement, making them suboptimal for initial management of severe presentations.",
                        "wrongAnswer_2": "First-line agents for severe disease are cyclosporine (CsA) and tacrolimus (TAC), both calcineurin inhibitors that block IL-2 production and T-cell activation, primarily utilized for acute control of inflammation and organ involvement, offering rapid immunosuppression, but their nephrotoxicity and hypertension risks limit their long-term use and necessitate careful monitoring, making them less favored for sustained management of severe disease.",
                        "wrongAnswer_3": "Severe refractory disease is best managed with TNF-alpha inhibitors (e.g., infliximab, adalimumab) and IL-1 inhibitors (e.g., anakinra). TNF-alpha inhibitors block pro-inflammatory cytokine signaling, while IL-1 inhibitors reduce systemic inflammation, primarily targeting joint inflammation and systemic symptoms, but they exhibit limited efficacy in managing renal or neurological involvement and are not typically first-line for organ-threatening disease manifestations.",
                        "wrongAnswer_4": "The primary approach for severe disease involves hematopoietic stem cell transplantation (HSCT) and gene therapy. HSCT aims to reset the immune system, potentially achieving disease remission, while gene therapy targets specific immune pathways for correction, offering potential cures for severe refractory cases, but both are highly experimental, carry significant risks of graft-versus-host disease, infection, and long-term complications, and are not considered standard first-line treatments for severe disease."
                    },
                    {
                        "question": "Beyond pharmacological interventions, what essential non-pharmacological strategies are integral to the holistic management of the disease, emphasizing lifestyle adjustments and supportive care measures that complement medical treatments?",
                        "goodAnswer": "Comprehensive non-pharmacological management includes rigorous sun protection using high SPF sunscreens and protective clothing to minimize UV-induced flares, regular moderate exercise to maintain musculoskeletal function and cardiovascular health, smoking cessation to mitigate cardiovascular risk and improve disease outcomes, and psychosocial support to address fatigue, depression, and enhance coping mechanisms. Additionally, dietary modifications focusing on anti-inflammatory foods, stress management techniques, and adherence to recommended vaccination schedules are crucial supportive measures that enhance overall well-being and disease control.",
                        "wrongAnswer_1": "Non-pharmacological strategies are primarily limited to complete bed rest during active flares to minimize joint stress and promote systemic healing, a high-protein, low-carbohydrate diet to counteract muscle wasting and reduce inflammation, and complete avoidance of all physical activity to prevent exacerbation of symptoms, with minimal emphasis on psychosocial support or lifestyle modifications beyond physical rest and dietary restrictions.",
                        "wrongAnswer_2": "Management mainly involves aggressive physical therapy and occupational therapy regimens to restore joint function and mobility, irrespective of disease activity levels, coupled with high-dose vitamin D supplementation to bolster immune function and prevent osteoporosis, and strict adherence to a ketogenic diet to achieve systemic metabolic control and inflammation reduction, with limited consideration for sun protection or psychological well-being as secondary supportive measures.",
                        "wrongAnswer_3": "Non-pharmacological approaches center on complete avoidance of all conventional medications to minimize potential side effects, rigorous fasting and detoxification protocols to eliminate purported bodily toxins, and spiritual healing practices to address the underlying spiritual causes of the disease, with minimal emphasis on evidence-based lifestyle adjustments, sun protection, or conventional supportive medical care, prioritizing alternative and unproven therapies.",
                        "wrongAnswer_4": "Management strategies predominantly consist of extreme cold therapy (cryotherapy) to reduce inflammation and pain symptoms, regular sauna sessions to promote detoxification and improve circulation, and complete social isolation to prevent opportunistic infections and minimize environmental stress, with little emphasis on sun protection, regular exercise, or psychosocial support, and potential risks associated with extreme temperature therapies and social isolation."
                    }
                ]
            }
        ],
        "team_name": "Bob\u00f3kocka"
    }
}
